^
Association details:
| Biomarker: | EML4-ALK variant 3 |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase 3 trial of lorlatinib in treatment-naive patients (Pts) with ALK-positive advanced non–small cell lung cancer (NSCLC): Comprehensive plasma and tumor genomic analyses.
Published date:
05/26/2022
Excerpt:
Based on ctDNA, ORRs were generally higher in the lorlatinib vs crizotinib arm, reaching 80% and 72% for EML4-ALK v1 and v3, respectively, in the lorlatinib arm, and 50% and 74% in the crizotinib arm....Pts with untreated ALK+ advanced NSCLC had higher ORRs and potentially longer PFS across predefined biomarker subgroups when treated with lorlatinib compared with crizotinib in the phase 3 CROWN study.
DOI:
10.1200/JCO.2022.40.16_suppl.9070
Trial ID:
Source:
Title:
EP16.03-012 - Novel Human-derived EML4-ALK Fusion cell lines identify ribonucleotide reductase RRM2 as a Target of Activated ALK in NSCLC
Published date:
07/12/2022
Excerpt:
In this study, we have confirmed the expression of the corresponding ALK fusion protein and assessed their sensitivity to a range of ALK tyrosine kinase inhibitors (TKIs). These patient-derived cell lines exhibit differential sensitivity to ALK TKIs, such as lorlatinib, brigatinib and alectinib, with EML4-ALK variant 3 containing cell lines exhibiting an increased sensitivity to lorlatinib and brigatinib as compared to alectinib.
